Triheptanoin Versus Trioctanoin for Long-chain Fatty Acid Oxidation Disorders: a Double Blinded, Randomized Controlled Trial

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2017 Sep 6

PMID 28871440

Citations 53

Authors

Melanie B Gillingham

Stephen B Heitner

Julie Martin

Sarah Rose

Amy Goldstein

Areeg Hassan El-Gharbawy

Stephanie Deward

Michael R Lasarev

Jim Pollaro

James P DeLany

Luke J Burchill

Bret Goodpaster

James Shoemaker

Dietrich Matern

Cary O Harding

Jerry Vockley

Affiliations

Soon will be listed here.

Abstract

Background: Observational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium-chain triglyceride (MCT) treatment of long-chain fatty acid oxidation disorders (LC-FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven-carbon fatty acid triglyceride, to trioctanoin (C8), an eight-carbon fatty acid triglyceride, in patients with LC-FAODs.

Methods: A double blinded, randomized controlled trial of 32 subjects with LC-FAODs (carnitine palmitoyltransferase-2, very long-chain acylCoA dehydrogenase, trifunctional protein or long-chain 3-hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis.

Results: Patients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate-intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups.

Conclusions: C7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC-FAODs.

Clinical Trial Registration: Clinicaltrials.gov NCT01379625.

Citing Articles

Anaplerotic filling in heart failure: a review of mechanism and potential therapeutics.

Alhasan K, King M, Pattar B, Lewis I, Lopaschuk G, Greenway S Cardiovasc Res. 2024; 120(17):2166-2178.

PMID: 39570879 PMC: 11687400. DOI: 10.1093/cvr/cvae248.

Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in Italy.

Porta F, Maiorana A, Gragnaniello V, Procopio E, Gasperini S, Taurisano R Ital J Pediatr. 2024; 50(1):204.

PMID: 39375714 PMC: 11460043. DOI: 10.1186/s13052-024-01782-y.

Nutritional Management of Patients with Fatty Acid Oxidation Disorders.

Pena-Quintana L, Correcher-Medina P Nutrients. 2024; 16(16).

PMID: 39203843 PMC: 11356788. DOI: 10.3390/nu16162707.

A high-fat diet supplemented with medium-chain triglycerides ameliorates hepatic steatosis by reducing ceramide and diacylglycerol accumulation in mice.

Mourad S, Abdualkader A, Li X, Jani S, Ceddia R, Al Batran R Exp Physiol. 2024; 109(3):350-364.

PMID: 38192209 PMC: 10988743. DOI: 10.1113/EP091545.

Long-term prognosis of fatty-acid oxidation disorders in adults: Optimism despite the limited effective therapies available.

Rouyer A, Tard C, Dessein A, Spinazzi M, Bedat-Millet A, Dimitri-Boulos D Eur J Neurol. 2023; 31(2):e16138.

PMID: 38015438 PMC: 11235989. DOI: 10.1111/ene.16138.

References

Saudubray J, Martin D, de Lonlay P, Touati G, Bonnet D, Jouvet P . Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999; 22(4):488-502. DOI: 10.1023/a:1005556207210. View

Bonnet D, Martin D, de Lonlay P, Villain E, Jouvet P, Rabier D . Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999; 100(22):2248-53. DOI: 10.1161/01.cir.100.22.2248. View

DeLany J, Windhauser M, Champagne C, Bray G . Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr. 2000; 72(4):905-11. DOI: 10.1093/ajcn/72.4.905. View

Rinaldo P, Matern D, Bennett M . Fatty acid oxidation disorders. Annu Rev Physiol. 2002; 64:477-502. DOI: 10.1146/annurev.physiol.64.082201.154705. View

Roe C, Sweetman L, Roe D, David F, Brunengraber H . Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002; 110(2):259-69. PMC: 151060. DOI: 10.1172/JCI15311. View

Gillingham M, Connor W, Matern D, Rinaldo P, Burlingame T, Meeuws K . Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2003; 79(2):114-23. PMC: 2813192. DOI: 10.1016/s1096-7192(03)00073-8. View

Roe C, Mochel F . Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006; 29(2-3):332-40. DOI: 10.1007/s10545-006-0290-3. View

Gillingham M, Scott B, Elliott D, Harding C . Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab. 2006; 89(1-2):58-63. PMC: 2706834. DOI: 10.1016/j.ymgme.2006.06.004. View

Neubauer S . The failing heart--an engine out of fuel. N Engl J Med. 2007; 356(11):1140-51. DOI: 10.1056/NEJMra063052. View

10.

Roe C, Yang B, Brunengraber H, Roe D, Wallace M, Garritson B . Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008; 71(4):260-4. PMC: 2676979. DOI: 10.1212/01.wnl.0000318283.42961.e9. View

11.

Arnold G, Van Hove J, Freedenberg D, Strauss A, Longo N, Burton B . A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2009; 96(3):85-90. PMC: 3219055. DOI: 10.1016/j.ymgme.2008.09.008. View

12.

Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner M, Boehles H . Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009; 32(4):498-505. DOI: 10.1007/s10545-009-1126-8. View

13.

Wilcken B . Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010; 33(5):501-6. DOI: 10.1007/s10545-009-9001-1. View

14.

Smith E, Matern D . Acylcarnitine analysis by tandem mass spectrometry. Curr Protoc Hum Genet. 2010; Chapter 17:Unit 17.8.1-20. DOI: 10.1002/0471142905.hg1708s64. View

15.

Lopaschuk G, Ussher J, Folmes C, Jaswal J, Stanley W . Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010; 90(1):207-58. DOI: 10.1152/physrev.00015.2009. View

16.

Lindner M, Hoffmann G, Matern D . Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010; 33(5):521-6. DOI: 10.1007/s10545-010-9076-8. View

17.

Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B . Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010; 33(5):555-61. DOI: 10.1007/s10545-010-9188-1. View

18.

Des Rosiers C, Labarthe F, Lloyd S, Chatham J . Cardiac anaplerosis in health and disease: food for thought. Cardiovasc Res. 2011; 90(2):210-9. PMC: 3078802. DOI: 10.1093/cvr/cvr055. View

19.

Lindner M, Gramer G, Haege G, Fang-Hoffmann J, Schwab K, Tacke U . Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany. Orphanet J Rare Dis. 2011; 6:44. PMC: 3141366. DOI: 10.1186/1750-1172-6-44. View

20.

Bennett M, Rinaldo P, Wilcken B, Pass K, Watson M, Wanders R . Newborn screening for metabolic disorders: how are we doing, and where are we going?. Clin Chem. 2011; 58(2):324-31. DOI: 10.1373/clinchem.2011.171215. View